

Supplemental Table.

Table. Ongoing clinical trials of sodium–glucose cotransporter-2 inhibitors in patients with or without type 2 diabetes and/or heart failure.

Study name (NCT identifier)	Indication Treatment	No. of patients	Primary outcome	Estimated completion date
DELIVER (NCT03619213)	HFpEF DAPA vs PBO	4700 ^a	CV death, hospitalization for HF, or urgent HF visit	June 2021
DETERMINE-Reduced (NCT03877237)	HFREF DAPA	300 ^a	Change from baseline in 6MWD at week 16	January 2020
DETERMINE-Preserved (NCT03877224)	HFpEF DAPA	400 ^a	Change from baseline in 6MWD at week 16	February 2020
EMPRISE (NCT03363464)	T2D EMPA vs DPP-4i	80,000	3-point MACE, hospitalization for HF, all-cause mortality	November 2021
EMPEROR-Reduced (NCT03057977)	HFREF EMPA vs PBO	2850 ^a	CV death or hospitalization for HF	June 2020
EMPEROR-Preserved (NCT03057951)	HFpEF EMPA vs PBO	4126 ^a	CV death or hospitalization for HF	June 2020
EMPERIAL-Reduced (NCT03448419)	HFREF EMPA vs PBO	300 ^a	Change in exercise capacity	December 2019
EMPERIAL-Preserved (NCT03448406)	HFpEF EMPA vs PBO	300 ^a	Change in exercise capacity	December 2019
SOLOIST-WHF (NCT03521934)	T2D + WHF SOTA vs PBO	4000 ^a	CV death or hospitalization for HF	January 2021

^aEstimated enrollment.

6MWD: 6-minute walk distance; CV: cardiovascular; DAPA: dapagliflozin; DPP-4i: dipeptidyl peptidase-4 inhibitor; EMPA: empagliflozin; HF: heart failure; HFpEF: HF with preserved

ejection fraction; HFrEF: HF with reduced ejection fraction; MACE: major adverse CV events; NA; not available; NCT: National Clinical Trial; PBO: placebo; SOTA: sotagliflozin; T2D: type 2 diabetes; WHF: worsening HF.